From Bacteria to Cancer: A Benzothiazole-Based DNA Gyrase B Inhibitor Redesigned for Hsp90 C-Terminal Inhibition
作者:Kyler W. Pugh、Zheng Zhang、Jian Wang、Xiuzhi Xu、Vitumbiko Munthali、Ang Zuo、Brian S. J. Blagg
DOI:10.1021/acsmedchemlett.0c00100
日期:2020.8.13
Heat shock protein 90 (Hsp90) is a molecular chaperone that is responsible for the folding and maturation of client proteins that are associated with all ten hallmarks of cancer. Hsp90 N-terminal pan inhibitors have experienced unfavorable results in clinical trials due to induction of the heat shock response (HSR), among other concerns. Novobiocin, a well characterized DNA gyrase B inhibitor, was
热休克蛋白 90 (Hsp90) 是一种分子伴侣,负责与癌症的所有十个标志相关的客户蛋白的折叠和成熟。由于热休克反应 (HSR) 的诱导以及其他问题,Hsp90 N 端泛抑制剂在临床试验中经历了不利的结果。Novobiocin 是一种充分表征的 DNA 促旋酶 B 抑制剂,被鉴定为第一个 Hsp90 C 末端抑制剂,它在不诱导 HSR 的情况下表现出抗癌作用。在这封信中,设计、合成和评估了一个源自苯并噻唑支架的 Hsp90 C 端抑制剂库,已知可抑制 DNA 促旋酶 B。发现几种化合物通过 Hsp90 C 末端抑制对 MCF-7 和 SKBr3 乳腺癌细胞系表现出低微摩尔活性。